Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2021-12-06 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
关于对第四届董事会第八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a board meeting resolution regarding the company's proposed asset purchase. It references regulatory guidelines and the company's articles but does not contain financial statements or detailed financial data. It is a formal opinion related to board/management decisions rather than a full report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management-level decision commentary, not a full report or announcement.
2021-12-06 Chinese
第四届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the eighth meeting of the fourth board of directors of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, and the approval of a proposal regarding asset purchase. The document includes voting results and mentions that the proposal does not require shareholder approval. It also references related documents for further details. This type of document is a Board/Management Information announcement, as it concerns board meeting decisions and management actions rather than a full report or financial statement.
2021-12-06 Chinese
关于成立静泉分公司并完成工商注册登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the establishment and registration of a new branch (静泉分公司) of the company 新乡拓新药业股份有限公司. It includes details about the registration, purpose, and impact of the new branch. There is no financial data, no mention of financial results, no regulatory certifications, or voting results. It is a corporate announcement about organizational structure but not about board or management changes. It does not fit into categories like Annual Report, Interim Report, or Capital Update. It is a general regulatory announcement about company operations and compliance with disclosure obligations. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2021-12-01 Chinese
关于子公司完成工商变更登记并换发营业执照的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a subsidiary completing industrial and commercial registration changes and obtaining a new business license. It includes details about the subsidiary's capital increase and registration information. The document is short (1081 characters) and does not contain financial statements or detailed financial data. It is an operational update related to corporate registration and capital increase to a subsidiary, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information about the registration and capital increase. The best fitting category is Capital/Financing Update (CAP) because it involves the use of raised funds to increase capital in a subsidiary and related registration changes.
2021-11-30 Chinese
2021年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the "2021 Second Extraordinary General Meeting of Shareholders" of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results on specific proposals, and legal opinions confirming the validity of the meeting and voting process. The content focuses on the official announcement of shareholder meeting resolutions and voting outcomes rather than the meeting materials or presentations themselves. The document length is relatively short (1983 characters), and it is a formal announcement of voting results from a shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-11-26 Chinese
2021年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of the 2021 second extraordinary general meeting (临时股东大会) of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the legality and validity of the meeting's call, attendance, and voting process. The document does not contain financial statements or management discussion but focuses on the legal validation of the shareholder meeting and its voting results. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and confirms the legitimacy of the shareholder meeting procedures.
2021-11-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.